Table 4. Factors Associated with mPAP on RHC in HIV-Infected Subjects.

A. mPAP
	Univariable	Multivariable
Parameter	% Estimate (95% CI), p-value	% Estimate (95% CI), p-value
ET-1 (per 0.1 pg/ml increase)	28% (-1%, 67%), p = 0.060	34% (11%, 63%), p = 0.003
Age (per decade)	-16% (-28%, -2%), p = 0.031	-17% (-29%, -4%), p = 0.015
Male vs. Female	1% (-15%, 19%), p = 0.946	3% (-15%, 26%), p = 0.733
African-American vs. Caucasian	-10% (-28%, 13%), p = 0.382	-1% (-18%, 20%), p = 0.918
Latino vs. Caucasian	2% (-33%, 55%), p = 0.926	12% (-25%, 68%), p = 0.567
Other vs. Caucasian	-28% (-46%, -5%), p = 0.023	-10% (-26%, 10%), p = 0.326
Stimulant IVDU (ever vs. never)	25% (0%, 56%), p = 0.047	16% (-4%, 40%), p = 0.137
B. PAH (mPAP ≥ 25 mmHg)
	Univariable	Multivariable
Parameter	PR (95% CI), p-value	PR (95% CI), p-value
ET-1 (per 0.1 pg/ml increase)	2.35 (1.07, 5.13), p = 0.033	2.39 (1.10, 5.20), p = 0.028
Age (per decade)	0.77 (0.49, 1.20), p = 0.246	0.69 (0.41, 1.14), p = 0.145
Male vs. Female	0.88 (0.30, 2.59), p = 0.820	0.96 (0.34, 2.70), p = 0.940
African American vs. Caucasian	0.92 (0.36, 2.35), p = 0.856	1.17 (0.44, 3.11), p = 0.754
Latino/Other vs. Caucasian	0.61 (0.15, 2.43), p = 0.485	1.05 (0.24, 4.56), p = 0.950

CI, confidence interval; ET-1, endothelin-1; IVDU, intravenous drug use; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PR, prevalence ratio; RHC, right heart catheterization.

Analysis includes the subgroup of 65 HIV-infected subjects who underwent RHC. mPAP is log-transformed; results are back-transformed to calculate estimated percentage differences in mPAP attributable to each covariate.